Catalent (CTLT) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a research report released on Friday morning. Zacks Investment Research currently has $45.00 price target on the stock.

According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

How to Become a New Pot Stock Millionaire

Several other equities analysts have also weighed in on CTLT. Royal Bank of Canada initiated coverage on shares of Catalent in a research report on Wednesday, December 13th. They set an outperform rating and a $46.00 price objective for the company. First Analysis began coverage on shares of Catalent in a report on Friday, January 5th. They issued an equal weight rating for the company. Goldman Sachs began coverage on shares of Catalent in a report on Wednesday, January 24th. They issued a buy rating and a $50.00 target price for the company. Stephens cut shares of Catalent from an overweight rating to an equal weight rating in a report on Tuesday, February 6th. Finally, Bank of America raised their target price on shares of Catalent from $47.00 to $49.00 and gave the stock a buy rating in a report on Tuesday, February 6th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $45.75.

NYSE:CTLT opened at $39.00 on Friday. Catalent has a twelve month low of $27.48 and a twelve month high of $47.87. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78. The stock has a market cap of $5,199.44, a PE ratio of 28.89, a price-to-earnings-growth ratio of 2.26 and a beta of 1.53.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The company had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. During the same quarter last year, the firm posted $0.27 EPS. The business’s revenue for the quarter was up 25.3% on a year-over-year basis. equities research analysts expect that Catalent will post 1.52 earnings per share for the current year.

In other Catalent news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the transaction, the senior vice president now directly owns 46,986 shares in the company, valued at $1,964,014.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. lifted its position in shares of Catalent by 14.8% in the fourth quarter. Meeder Asset Management Inc. now owns 9,445 shares of the company’s stock worth $388,000 after purchasing an additional 1,218 shares in the last quarter. First Bank & Trust lifted its position in shares of Catalent by 54.2% in the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock worth $155,000 after purchasing an additional 1,323 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Catalent by 5.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 29,439 shares of the company’s stock worth $1,209,000 after purchasing an additional 1,430 shares in the last quarter. SG Americas Securities LLC raised its position in Catalent by 4.1% during the fourth quarter. SG Americas Securities LLC now owns 39,984 shares of the company’s stock valued at $1,643,000 after acquiring an additional 1,579 shares in the last quarter. Finally, Strs Ohio raised its position in Catalent by 7.4% during the fourth quarter. Strs Ohio now owns 23,300 shares of the company’s stock valued at $957,000 after acquiring an additional 1,600 shares in the last quarter. 99.89% of the stock is owned by institutional investors and hedge funds.

WARNING: “Catalent (CTLT) Upgraded at Zacks Investment Research” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3342446/catalent-ctlt-upgraded-at-zacks-investment-research.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

RHFCoin Trading 3% Higher  Over Last Week
RHFCoin Trading 3% Higher Over Last Week
HomeBlockCoin Achieves Market Capitalization of $80,948.00
HomeBlockCoin Achieves Market Capitalization of $80,948.00
Comparing Ensign Group  & Genesis HealthCare
Comparing Ensign Group & Genesis HealthCare
Contrasting Moelis & Company  & The Competition
Contrasting Moelis & Company & The Competition
Financial Comparison: Intrexon  versus Sorrento Therapeutics
Financial Comparison: Intrexon versus Sorrento Therapeutics
$713.23 Million in Sales Expected for Genesis Energy, L.P.  This Quarter
$713.23 Million in Sales Expected for Genesis Energy, L.P. This Quarter


Leave a Reply

© 2006-2018 Ticker Report. Google+.